• Exploding research volume: 75,000+ intervention studies for Alzheimer’s alone; hundreds of new longevity papers released every week.

• Multiscale complexity: Longevity spans molecular → cellular → systemic → behavioral levels — each with distinct data types, models, and methodologies.

• Integration bottleneck: Capturing cross-scale interactions (e.g., interventions, biomarkers, pathways) requires laborious manual synthesis of rapidly evolving data.

• Ephemeral insights: By the time datasets and findings are integrated, new studies emerge, deprecating much of the previous effort.

Bottom line: Unlocking and unifying this multiscale data could drastically accelerate discovery across the longevity industry.

• Pharma co-development: Partner with pharmaceutical companies; earn profit shares from drugs developed using our platform.

• Lifestyle optimization SaaS: Subscription model for wellness companies or consumers — personalize and visualize network effects of lifestyle interventions.

• Investor intelligence tool: Neutral analytics platform helping investors evaluate biotech pitches, verifying that off-target risks are properly addressed.